Pulike Biological Engineering, Inc. (603566.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 10.11

From 52W high−30.24%

Volume2.04M

Market capCNY 3.54B

P/E (TTM)19.1x

P/S (TTM)3.3x

Div yield5.93%

Key dataSep 18, 2026

Open

CNY 10.11

From 52W high

−30.24%

Volume

2.04M

Market cap

CNY 3.54B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.8x

P/E (TTM)

19.1x

RSI (14)

42.2

MomentumView details →

1D Return

−0.68%

YTD Return

−18.58%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

19.1x

EV/EBITDA

10.8x

EV/Sales

3.4x

P/S (TTM)

3.3x

P/B (TTM)

1.4x

ProfitabilityView details →

Gross Margin

58.74%

Net Margin

16.30%

EBITDA Margin

30.99%

ROE (TTM)

6.53%

ROA (TTM)

5.37%

Asset Turnover

0.33x

GrowthView details →

Revenue YoY

−2.32%

EPS YoY

+45.69%

FCF YoY

−19.03%

Revenue CAGR 3Y

−3.95%

EPS CAGR 3Y

+1.27%

EBITDA YoY

—

MomentumView details →

1D Return

−0.68%

YTD Return

−18.58%

1Y Return

−27.30%

RSI (14)

42.2

vs 50D SMA

−2.50%

vs 200D SMA

−14.67%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

3.82x

Quick Ratio

3.19x

Div Yield

5.93%

Div Rate

CNY 0.60

Div Growth 1Y

+50.00%

EarningsView details →

EPS (Actual)

CNY 0.11

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

0.00%

Financials snapshotView financials →

Revenue (TTM)

1.06B

Net Income (TTM)

172.82M

Op. CF (TTM)

272.92M

Next earningsOct 22, 2026 →

Latest newsMore news →

Pulike's wholly owned subsidiary Luoyang Huizhong Veterinary Medicine received a Class II new veterinary drug registration certificate from China's Ministry of Agriculture and Rural Affairs for Denaverine Hydrochloride Injection on September 14, 2026.6d ago

Pulike Biological Engineering announced its H1 2026 results with revenue of 491 million yuan, down 12.18% year-on-year, and net profit attributable to shareholders of 77.32 million yuan, down 33.45% year-on-year.27d ago

Similar companies

硕世生物688399.SH Enliven Therapeutics, Inc.ELVN Shanghai Haohai Biological Technology Co., Ltd.06826.HK Legend Biotech CorporationLEGN Tarsus Pharmaceuticals, Inc.TARS Mirxes Holding Company Limited02629.HK Find similar companies →

Latest newsMore news →

Pulike's wholly owned subsidiary Luoyang Huizhong Veterinary Medicine received a Class II new veterinary drug registration certificate from China's Ministry of Agriculture and Rural Affairs for Denaverine Hydrochloride Injection on September 14, 2026.6d ago Pulike Biological Engineering announced its H1 2026 results with revenue of 491 million yuan, down 12.18% year-on-year, and net profit attributable to shareholders of 77.32 million yuan, down 33.45% year-on-year.27d ago